← Back to Search
Medicinal Inorganic Chemistry: Metal‐containing Diagnostic Compounds
Published 2011 · Chemistry
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Metallopharmaceuticals designed for use in diagnostic compounds cover a broad spectrum of diagnostic modalities, starting with barium sulfate for enhanced X-ray contrast, to the hugely successful gadolinium-based magnetic resonance imaging (MRI) contrast agents, to more recent advances in positron emission tomography (PET) and single photon emission computed tomography (SPECT) requiring radiolabeled metal-based diagnostic agents for image detection. In each case, the pharmacokinetics of tissue distribution and the thermodynamic stability of the metal-ligand coordination complex are very important to the clinical utility of the particular compound. For radiolabeling, the speed and ease of radiolabel production are also key features of the metallodiagnostic agent's utility. Keywords: MRI; contrast agent; SPECT; PET; rubidium; gadolinium; 64Cu; 68Ga; 67Ga; 18F; 99mTc; bifunctional metallopharmaceutical
This paper references
Image Formation by Induced Local Interactions: Examples Employing Nuclear Magnetic Resonance
P. Lauterbur (1973)
Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design
R. Lauffer (1987)
Solution structure and dynamics of lanthanide(III) complexes of diethylenetriaminepentaacetate: a two-dimensional NMR analysis
B. Jenkins (1988)
The relationship between thermodynamics and the toxicity of gadolinium complexes.
W. Cacheris (1990)
Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease.
R. Stewart (1991)
Dissociation of gadolinium chelates in mice: relationship to chemical characteristics.
P. Wedeking (1992)
Coordination compounds in nuclear medicine
S. Jurisson (1993)
Gadolinium complex of tris[(3-hydroxy-1-methyl- 2-oxo-1,2-didehydropyridine-4-carboxamido)ethyl]-amine: A New Class of gadolinium magnetic resonance relaxation agents
J. Xu (1995)
Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI.
S. Young (1996)
Lanthanide(III) chelates for NMR biomedical applications
S. Aime (1998)
The biomedical chemistry of technetium and rhenium
J. R. Dilworth (1998)
Metals in Medicine.
Zijian Guo (1999)
Metal-Based X-ray Contrast Media.
S. Yu. (1999)
99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.
S. Liu (1999)
Radiometal-Labeled Agents (Non-Technetium) for Diagnostic Imaging
C. Anderson (1999)
Potential technetium small molecule radiopharmaceuticals.
S. Jurisson (1999)
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications.
P. Caravan (1999)
Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles
S. Anderson (2000)
[GdPCP2A(H2O)2]-: A Paramagnetic Contrast Agent Designed for Improved Applications in Magnetic Resonance Imaging
S. Aime (2000)
Syntheses and relaxation properties of mixed gadolinium hydroxypyridinonate MRI contrast agents.
S. Cohen (2000)
Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy.
J. Sessler (2000)
In vivo visualization of gene expression using magnetic resonance imaging
A. Louie (2000)
Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals.
S. Liu (2001)
pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation.
M. P. Lowe (2001)
An unusual dimeric structure of a Cu(I) bis(thiosemicarbazone) complex: implications for the mechanism of hypoxic selectivity of the Cu(II) derivatives.
A. Cowley (2002)
New Classes of MRI Contrast Agents
Vincent Jacques (2002)
Biomedical uses and applications of inorganic chemistry. An overview
Nicholas Farrell (2002)
Relaxivity of MRI Contrast Agents
É. Tóth (2002)
Current use and future potential of organometallic radiopharmaceuticals
R. Schibli (2002)
Insights into the use of paramagnetic Gd(III) complexes in MR‐molecular imaging investigations
S. Aime (2002)
Mechanistic studies of a calcium-dependent MRI contrast agent.
W. Li (2002)
The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates.
P. Caravan (2002)
The effect of ligand scaffold size on the stability of tripodal hydroxypyridonate gadolinium complexes.
B. O'sullivan (2003)
New magnetic resonance contrast agents as biochemical reporters
T. Meade (2003)
An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis.
M. E. Bartolini (2003)
Toward optimized high-relaxivity MRI agents: the effect of ligand basicity on the thermodynamic stability of hexadentate hydroxypyridonate/catecholate gadolinium(III) complexes.
D. M. Doble (2003)
Carbohydrate conjugates for molecular imaging and radiotherapy: 99mTc(I) and 186Re(I) tricarbonyl complexes of N-(2'-Hydroxybenzyl)-2-amino-2-deoxy-D-glucose.
S. Bayly (2004)
Gadolinium(III) 1,2-hydroxypyridonate-based complexes: toward MRI contrast agents of high relaxivity.
J. Xu (2004)
Toward optimized high-relaxivity MRI agents: thermodynamic selectivity of hydroxypyridonate/catecholate ligands.
V. C. Pierre (2004)
All Science Is Interdisciplinary—From Magnetic Moments to Molecules to Men (Nobel Lecture)
P. Lauterbur (2005)
Multilocus binding increases the relaxivity of protein-bound MRI contrast agents.
Z. Zhang (2005)
Radiohalogens for imaging and therapy.
M. Adam (2005)
Next generation, high relaxivity gadolinium MRI agents.
K. Raymond (2005)
A glucosamine-dipicolylamine conjugate of 99mTc(I) and 186Re(I) for use in imaging and therapy.
T. Storr (2005)
Benefiting from the unique properties of lanthanide ions.
Jean-Claude G Bünzli (2006)
Quantitative Imaging of Cell-Permeable Magnetic Resonance Contrast Agents Using X-Ray Fluorescence
Paul J H Endres (2006)
A smart magnetic resonance contrast agent for selective copper sensing.
E. L. Que (2006)
Metal complexes of maltol and close analogues in medicinal inorganic chemistry.
K. Thompson (2006)
Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.
P. Caravan (2006)
Tris(pyrone) chelates of Gd(III) as high solubility MRI-CA.
D. Puerta (2006)
Design of targeting ligands in medicinal inorganic chemistry.
T. Storr (2006)
Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.
A. Vāvere (2007)
Use of lanthanide-grafted inorganic nanoparticles as effective contrast agents for cellular uptake imaging.
P. Voisin (2007)
Toward improved syntheses of dendrimer-based magnetic resonance imaging contrast agents: new bifunctional diethylenetriaminepentaacetic acid ligands and nonaqueous conjugation chemistry.
H. Xu (2007)
A new bisphosphonate-containing 99mTc(I) tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation
E. Palma (2007)
Potentiometric and relaxometric properties of a gadolinium-based MRI contrast agent for sensing tissue pH.
F. Kálmán (2007)
Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent.
P. Caravan (2007)
Collagen-targeted MRI contrast agent for molecular imaging of fibrosis.
P. Caravan (2007)
Multimodal MRI contrast agents
Luca Frullano (2007)
Water-soluble contrast agents targeted at the estrogen receptor for molecular magnetic resonance imaging.
C. Gunanathan (2007)
Determinants of the response of left ventricular ejection fraction to vasodilator stress in electrocardiographically gated 82rubidium myocardial perfusion PET
T. Brown (2007)
Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis.
M. Perazella (2008)
Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. insights into mechanisms of copper uptake and hypoxia selectivity.
Z. Xiao (2008)
Cell-permeable MR contrast agents with increased intracellular retention.
Paul J H Endres (2008)
High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging.
E. J. Werner (2008)
99m-Technetium carbohydrate conjugates as potential agents in molecular imaging.
M. Bowen (2008)
Molecular imaging with PET.
S. Ametamey (2008)
EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.
Kirsten Overoye-Chan (2008)
Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C
T. Frenzel (2008)
99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer.
Jiyun Shi (2008)
A benzene-core trinuclear GdIII complex: towards the optimization of relaxivity for MRI contrast agent applications at high magnetic field.
J. B. Livramento (2008)
Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes.
P. Hermann (2008)
Synthesis and biodistribution of lipophilic and monocationic gallium radiopharmaceuticals derived from N,N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine: potential agents for PET myocardial imaging with 68Ga.
Yui-May Hsiao (2009)
1,2-hydroxypyridonate/terephthalamide complexes of gadolinium(III): synthesis, stability, relaxivity, and water exchange properties.
Eric J. Werner (2009)
A lysine walk to high relaxivity collagen-targeted MRI contrast agents.
P. Caravan (2009)
Bioresponsive, cell-penetrating, and multimeric MR contrast agents.
Jody L. Major (2009)
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.
T. Wadas (2010)